**Core Concept**
The patient's presentation is suggestive of Thrombotic Thrombocytopenic Purpura (TTP), a blood disorder characterized by the formation of blood clots in small blood vessels throughout the body. This leads to microangiopathic hemolytic anemia, thrombocytopenia, renal failure, and neurological symptoms.

**Why the Correct Answer is Right**
TTP is caused by a deficiency of ADAMTS13, a metalloprotease enzyme responsible for cleaving and regulating von Willebrand factor. The absence of this enzyme leads to the accumulation of ultra-large von Willebrand factor multimers, which cause platelet aggregation and thrombus formation. The patient's symptoms, including fever, altered consciousness, anemia with fragmented red blood cells, thrombocytopenia, and renal failure, are consistent with TTP. The treatment of choice for TTP is plasma exchange, which replaces the deficient ADAMTS13 enzyme and removes ultra-large von Willebrand factor multimers.

**Why Each Wrong Option is Incorrect**
**Option A:** Corticosteroids are not the primary treatment for TTP. While corticosteroids may be used to treat other conditions that cause thrombocytopenia, such as immune thrombocytopenia, they are not effective in treating TTP.

**Option B:** Platelet transfusions are not recommended in TTP, as they can actually worsen the condition by introducing more platelets that will be destroyed by the ultra-large von Willebrand factor multimers.

**Option C:** Rho(D) immune globulin is used to prevent RhD alloimmunization in RhD-negative women, but it is not used to treat TTP.

**Option D:** This option is not provided, so we cannot evaluate it.

**Clinical Pearl / High-Yield Fact**
The pentad of symptoms associated with TTP includes fever, thrombocytopenia, microangiopathic hemolytic anemia, renal failure, and neurological symptoms. Remember that TTP is a medical emergency that requires prompt treatment with plasma exchange.

**Correct Answer: A. Plasma exchange.**